Clinical trials: Worsening Chronic Heart Failure
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
The purpose of this study was to assess the effect of LCZ696 at a target dose of 200 mg b.i.d. compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF) treatment, on delaying time to first occurrence…
- Trial name
- PARALLEL-HF (NCT02468232)
- Testing
- LCZ696, Enalapril
- Where
- 49 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Outpatients With Chronic Heart Failure, Heart Failure Chronic
Biomarker Panel Development for Early Identification of Worsening Heart Failure and Improved Post-acute Care
Heart failure is a complex clinical syndrome with high hospitalization rates and high mortality risks. While N-terminal-pro B-type natriuretic peptide (NT-proBNP) is widely used in clinical practice to assist in diagnosis and…
- Trial name
- NCT07838766
- Volunteers
- 800 people
- Sponsor
- Chang Gung Memorial Hospital
Worsening Chronic Heart Failure, Diabetic Nephropathy
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic…
- Trial name
- NCT04881994
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Heart Failure
International Multi-center Study to Validate an Early Warning Algorithm for Worsening Heart Failure
The study is a multi-center, prospective, non-randomized, observational study to collect data to develop and validate a machine learning algorithm for early detection of worsening heart failure events using multi-parametric…
- Trial name
- VESTA (NCT04758429)
- Testing
- Machine-learning Algorithm
- Volunteers
- 552 people
- Sponsor
- Chronolife
Acute Decompensated Heart Failure; Renal Dysfunction
Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure
The purpose of this study is to determine the efficacy and safety of IV SLV320 in acute heart failure patients with renal dysfunction.
- Trial name
- NCT00744341
- Testing
- SLV320
- Where
- 105 sites in United States, Canada and 9 more
- Volunteers
- 46 people
- Sponsor
- Solvay Pharmaceuticals
Ischemic Heart Failure, Chronic Heart Failure
Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure
This study is designed to evaluate the safety and efficacy of allogeneic induced pluripotent cell derived cardiomyocytes (iPSC-CMs) in treating patients with worsening ischemic heart failure undergoing coronary artery bypass…
- Trial name
- NCT05566600
- Testing
- Human (allogeneic) iPS-cell-derived cardiomyocyte
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Heart Failure, Heart Failure With Preserved Ejection Fraction
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
- Trial name
- NCT05592275
- Testing
- LY3540378
- Where
- 137 sites in United States, Argentina and 10 more
- Volunteers
- 332 people
- Sponsor
- Eli Lilly and Company
COPD, CHF
Heart Failure Worsens Muscle Strength in COPD
The combination of heart failure (HF) and chronic obstructive pulmonary disease (COPD) is highly prevalent, but underdiagnosed and poorly recognized.
- Conditions
- COPD, CHF, Muscle Weakness
- Trial name
- NCT04261452
- Testing
- isokinetic dynamometer, Cardiopulmonary Exercise Test, Functional Capacity Tests
- Volunteers
- 50 people
- Sponsor
- Mayron Faria de Oliveira
Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system…
- Trial name
- NEUTRALIZE-CRS (NCT03836482)
- Testing
- Selective Cytopheretic Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SeaStar Medical
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced…
- Trial name
- NCT01951625
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 157 sites in United States, Australia and 22 more
- Volunteers
- 456 people
- Sponsor
- Bayer
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart…
- Trial name
- NCT01951638
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 158 sites in United States, Australia and 23 more
- Volunteers
- 477 people
- Sponsor
- Bayer
Congestive Heart Failure
EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan
The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).
- Trial name
- NCT00071331
- Testing
- Tolvaptan
- Where
- 378 sites in United States, Argentina and 16 more
- Volunteers
- 3,600 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Heart Failure
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic…
- Trial name
- ARTS-HF (NCT01807221)
- Testing
- Finerenone (BAY94-8862), Inspra (eplerenone)
- Where
- 172 sites in United States, Australia and 23 more
- Volunteers
- 1,066 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction, Worsening Heart Failure
A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction (HFrEF). HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body…
- Trial name
- NCT05658458
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- 12 sites in India
- Volunteers
- 205 people
- Sponsor
- Bayer
Heart Failure, Chronic Systolic Heart Failure
SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)
The purpose of this clinical trial is to see if a new device (SCD) is safe and if it can reduce damage to the kidney enough to allow medications to work to improve heart and kidney function for use in patients that have moderate…
- Conditions
- Heart Failure, Chronic Systolic Heart Failure, Renal Failure, Cardiorenal Syndrome
- Trial name
- NCT04589065
- Testing
- Selective Cytopheretic Device
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lenar Yessayan
Congestive Heart Failure Chronic, Cognitive Impairment, Mild
Depressive Symptoms, Cognitive Impairment, and Outcomes in Hospitalized Chronic Heart Failure Patients
The goal of this observational study is to learn about the prevalence of depressive symptoms and cognitive impairment and their association with worse outcomes in a cohort of hospitalized patients between the ages of 18 ang 85…
- Conditions
- Congestive Heart Failure Chronic, Cognitive Impairment, Mild, Depressive Symptoms Mild to Moderate in Severity
- Trial name
- DSCI-CHF (NCT07284446)
- Where
- Lithuania
- Volunteers
- 300 people
- Sponsor
- Lithuanian University of Health Sciences
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca
Chronic Heart Failure With Reduced Ejection Fraction, Worsening Chronic Heart Failure
An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions
This is an observational study in which data already collected from people with chronic HFrEF (heart failure with reduced ejection fraction) who have experienced worsening heart failure are studied.
- Trial name
- NCT06632483
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- India
- Volunteers
- 604 people
- Sponsor
- Bayer
Chronic Heart Failure
Adaptive Servo-ventilation Monitoring Study
Sleep disordered breathing is very common in patients with chronic heart failure with reported prevalence rates of 50-75%. Adaptive Servo-Ventilation (ASV) can be used to treat sleep apnea in these patients.
- Trial name
- NCT02133859
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- ResMed
Heart Failure
Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone
This study will be conducted in subjects with clinical diagnosis of worsening chronic heart failure and either type 2 diabetes mellitus (DM) with or without chronic kidney disease (CKD) or moderate CKD alone treated with…
- Trial name
- ARTS-HF Japan (NCT01955694)
- Testing
- BAY94-8862, Eplerenone
- Where
- 29 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Bayer